10.26.2013 | Forbes
By Steve Brozak
I am often asked to comment on a range of medical treatments – from new drugs to medical devices and procedures. Investors will inquire about a new treatment or procedure to gauge the likelihood of a product’s success, or to understand if there is a market for a particular treatment. But recently, and with greater frequency, I have been getting calls from individuals detailing obstacles they face to receiving medical treatment. Many of these calls concern costly and essential treatments or procedures, and with growing frequency, these callers have been denied reimbursement by their insurance companies.
For the full article, click here.
